Before the sun even came up on the Houston offices of Encysive Pharmaceuticals last Monday, Chief Executive Bruce Given got on a conference call with edgy financial analysts. Their question: Why had the U.S. Food and Drug Administration delayed approving Encysive’s Thelin, keeping the key drug off the market for another year?
